Key result
Intravenous X-537A increases max dP/dt by ~68% in anesthetized dogs.
Why the study?
Does the calcium ionophore X-537A improve myocardial contractility in normal anesthetized dogs?
Does the calcium ionophore X-537A improve myocardial contractility in normal anesthetized dogs?
Effect estimate: 68% increase
p-value: p=<.001
The calcium ionophore X-537A produces a rapid, sustained, and significant increase in myocardial contractility and cardiac output in anesthetized dogs, suggesting potential utility as an inotropic agent.
Hypothesis-generating for ionophore inotropes; leaves open human efficacy, safety, and translation.
The ability of ion permeability-inducing agents (ionophores) to complex and transport cations and amines across membranes has provided a novel approach for the pharmacological modification of biological systems. Of particular interest is X-537A, since it not only transports alkali ions but compared to most of the known ionophores it is unusually efficient in transporting calcium as well as catecholamines. The cardiovascular effects of this agent were studied in normal anesthetized dogs. X-537A produced a dramatic augmentation of myocardial contractility with up to 210% increases in max dP/dt after intravenous doses of 1.0-1.5 mg/kg. The moderate dose of 0.5-0.75 mg/kg X-537A induced significant increases in max dP/dt (68%, P < .001), isometric ventricular segmental tension (IVST) (79%, P < .01), peak dT/dt (65%, P < .05), cardiac output (44%, P < .001), aortic systolic (18%, P < .001) and diastolic (15%, P < .001) pressures, pulse pressure (28%, P < .001), left ventricular systolic pressure (18%, P < .001), and decrease in total peripheral resistance (23%, P < .05) without significant changes in heart rate and atrioventricular conduction. Beta-blockade with large doses of propranolol showed 20% suppression of the cardiac inotropism of X-537A. The action of X-537A is typically rapid with a smooth continuous progression until maximal response is attained in 10-15 minutes, sustained for about one hour, then gradually subsides during the third hour. Such ideal cardiovascular effects of X-537A portend a profound therapeutic potential in cases of cardiac decompensation and circulatory compromise. X-537A may also prove to be a valuable tool for probing the complex factors influencing myocardial contractility.
No takes yet. Share an insight, caveat, or question.
Guzman et al. (1974) studied Normal anesthetized dogs. X-537A was evaluated on max dP/dt (myocardial contractility) (68% increase, p=<.001). Intravenous administration of X-537A in anesthetized dogs significantly increased myocardial contractility, including a 68% increase in max dP/dt at moderate doses (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: